HealthCare Global Enterprises Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

HealthCare Global Enterprises wird ein jährliches Gewinn- und Umsatzwachstum von 48.2% bzw. 14.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 50.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.1% betragen.

Wichtige Informationen

48.2%

Wachstumsrate der Gewinne

50.4%

EPS-Wachstumsrate

Healthcare Gewinnwachstum27.3%
Wachstumsrate der Einnahmen14.5%
Zukünftige Eigenkapitalrendite14.1%
Analystenabdeckung

Good

Zuletzt aktualisiert14 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

HealthCare Global Enterprises Limited Just Missed Earnings - But Analysts Have Updated Their Models

Nov 13
HealthCare Global Enterprises Limited Just Missed Earnings - But Analysts Have Updated Their Models

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Feb 11
HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Recent updates

HealthCare Global Enterprises Limited Just Missed Earnings - But Analysts Have Updated Their Models

Nov 13
HealthCare Global Enterprises Limited Just Missed Earnings - But Analysts Have Updated Their Models

We Take A Look At Why HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation Is Well Earned

Sep 19
We Take A Look At Why HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation Is Well Earned

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Feb 11
HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

We Think Shareholders Will Probably Be Generous With HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation

Sep 14
We Think Shareholders Will Probably Be Generous With HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation

A Look At The Fair Value Of HealthCare Global Enterprises Limited (NSE:HCG)

Sep 05
A Look At The Fair Value Of HealthCare Global Enterprises Limited (NSE:HCG)

HealthCare Global Enterprises Limited's (NSE:HCG) Business Is Yet to Catch Up With Its Share Price

May 17
HealthCare Global Enterprises Limited's (NSE:HCG) Business Is Yet to Catch Up With Its Share Price

Does HealthCare Global Enterprises (NSE:HCG) Have A Healthy Balance Sheet?

Jun 24
Does HealthCare Global Enterprises (NSE:HCG) Have A Healthy Balance Sheet?

Shareholders Shouldn’t Be Too Comfortable With HealthCare Global Enterprises' (NSE:HCG) Strong Earnings

Jun 03
Shareholders Shouldn’t Be Too Comfortable With HealthCare Global Enterprises' (NSE:HCG) Strong Earnings

Is HealthCare Global Enterprises (NSE:HCG) Using Too Much Debt?

Dec 08
Is HealthCare Global Enterprises (NSE:HCG) Using Too Much Debt?

What Does HealthCare Global Enterprises Limited's (NSE:HCG) Share Price Indicate?

Jun 25
What Does HealthCare Global Enterprises Limited's (NSE:HCG) Share Price Indicate?

Insider Buying: The HealthCare Global Enterprises Limited (NSE:HCG) Executive Chairman Just Bought ₹2.4m Worth Of Shares

Mar 14
Insider Buying: The HealthCare Global Enterprises Limited (NSE:HCG) Executive Chairman Just Bought ₹2.4m Worth Of Shares

The HealthCare Global Enterprises (NSE:HCG) Share Price Is Up 51% And Shareholders Are Holding On

Mar 03
The HealthCare Global Enterprises (NSE:HCG) Share Price Is Up 51% And Shareholders Are Holding On

Here's Why HealthCare Global Enterprises (NSE:HCG) Can Afford Some Debt

Jan 27
Here's Why HealthCare Global Enterprises (NSE:HCG) Can Afford Some Debt

Gewinn- und Umsatzwachstumsprognosen

NSEI:HCG - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
3/31/202729,5172,0102,3455,3016
3/31/202625,6821,1651,3824,4069
3/31/202522,559770-8093,5248
9/30/202420,4365709233,468N/A
6/30/202419,770526N/AN/AN/A
3/31/202419,1214829892,846N/A
12/31/202318,592353N/AN/AN/A
9/30/202318,1403719222,197N/A
6/30/202317,471309N/AN/AN/A
3/31/202316,9442931,1842,516N/A
12/31/202216,174270N/AN/AN/A
9/30/202215,507-2641,1562,364N/A
6/30/202214,827694N/AN/AN/A
3/31/202213,9785371,4892,201N/A
12/31/202113,312-544N/AN/AN/A
9/30/202112,472-3791,0891,510N/A
6/30/202111,431-1,633N/AN/AN/A
3/31/202110,134-1,9358511,205N/A
12/31/20209,858-1,349N/AN/AN/A
9/30/20209,897-1,2847511,271N/A
6/30/202010,202-1,284N/AN/AN/A
3/31/202010,956-1,0672231,301N/A
12/31/201910,832-718N/AN/AN/A
9/30/201910,541-552N/AN/AN/A
6/30/201910,210-394N/AN/AN/A
3/31/20199,787-248-903985N/A
12/31/20189,430-135N/AN/AN/A
9/30/20189,004-41N/AN/AN/A
6/30/20188,661124N/AN/AN/A
3/31/20188,307205N/A978N/A
12/31/20177,909257N/AN/AN/A
9/30/20177,608278N/AN/AN/A
6/30/20177,237219N/AN/AN/A
3/31/20177,001230N/A913N/A
12/31/20166,705208N/AN/AN/A
9/30/20166,392133N/AN/AN/A
6/30/20166,08167N/AN/AN/A
3/31/20165,842-178N/A732N/A
12/31/20155,611-33N/AN/AN/A
9/30/20155,4949N/A763N/A
6/30/20155,3239N/AN/AN/A
3/31/20155,1948N/A597N/A
3/31/20144,513-356N/A514N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HCGDas prognostizierte Gewinnwachstum (48.2% pro Jahr) liegt über der Sparquote (6.7%).

Ertrag vs. Markt: HCGDie Erträge des Unternehmens (48.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (18% pro Jahr).

Hohe Wachstumserträge: HCGEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: HCGDie Einnahmen des Unternehmens (14.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10.4% pro Jahr).

Hohe Wachstumseinnahmen: HCGDie Einnahmen des Unternehmens (14.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: HCGDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.1%).


Wachstumsunternehmen entdecken